Cancer patients with tumors of similar grading, staging and histogenesis can have markedly different treatment responses to different chemotherapy agents. So far, individual markers have failed to correctly predict resistance against anticancer agents. We tested 30 cancer cell lines for sensitivity to 5-fluorouracil, cisplatin, cyclophosphamide, doxorubicin, etoposide, methotrexate, mitomycin C, mitoxantrone, paclitaxel, topotecan and vinblastine at drug concentrations that can be systemically achieved in patients. The resistance index was determined to designate the cell lines as sensitive or resistant, and then, the subset of resistant vs. sensitive cell lines for each drug was compared. Gene expression signatures for all cell lines were obtained by interrogating Affymetrix U133A arrays. Prediction Analysis of Microarrays was applied for feature selection. An individual prediction profile for the resistance against each chemotherapy agent was constructed, containing 42-297 genes. The overall accuracy of the predictions in a leave-oneout cross validation was 86%. A list of the top 67 multidrug resistance candidate genes that were associated with the resistance against at least 4 anticancer agents was identified. Moreover, the differential expressions of 46 selected genes were also measured by quantitative RT-PCR using a TaqMan micro fluidic card system. As a single gene can be correlated with resistance against several agents, associations with resistance were detected all together for 76 genes and resistance phenotypes, respectively. This study focuses on the resistance at the in vivo concentrations, making future clinical cancer response prediction feasible. The TaqManvalidated gene expression patterns provide new gene candidates for multidrug resistance. Supplementary material for this article can be found on the International Journal of Cancer website at
The major cause of failure of successful cancer treatment is resistance to currently available antineoplastic agents. Resistance can occur to individual anticancer drugs or more broadly to multiple drugs with different chemical structures and different mechanisms of action. This latter form of drug resistance is commonly designated as multidrug resistance (MDR). Many different mechanisms of MDR have been identified. These mechanisms include reduced cellular drug accumulation mediated by enhanced drug extrusion activity by members of the family of adenosine triphosphate-binding cassette (ABC)-transporters, e.g. MDR1/P-glycoprotein (P-gp), modulations of apoptotic pathways, alterations in cell cycle checkpoints, repair of damaged cellular targets, and various more or less well-characterized mechanisms. 1 In particular cancers, these mechanisms may act simultaneously and may influence each other, so that clinical MDR is a complex multifactorial problem.
From the clinician's point of view, the aim of drug resistance research is to improve treatment outcome by devising strategies that are able to circumvent primary drug resistance or to prevent the development of secondary antineoplastic drug resistance. Moreover, the detailed knowledge about the drug resistance status of a given patient with cancer can provide the basis for an individ-ual patient-tailored chemotherapy regiment in the future. To achieve this aim, an exact prediction of the resistance status of a tumor patient is necessary.
Although different MDR mechanisms have been associated with poor treatment outcome in particular cancers, 2 the breakthrough in prediction of drug resistance for cancer treatment is missing. Neither the clinical use of drug resistance reversal agents, e.g. ABC-transporter inhibitors, nor an individual treatment protocol led to significant benefits for the cancer patients. The reasons for these failures are complex. So far, different clinical trials using MDR reversing agents were performed without a pretherapeutic detection of the drug resistance status. 3 If a specific MDR factor is not active in the drug-resistant tumor, a specific inhibitor targeting this factor will not work. Another important problem arises from the fact, that the diagnosis of the MDR status is not standardized. For example, the immunohistochemical detection of MDR1/P-gp depends on various parameters, such as different antibodies with different specificity and cross-reactions, difficulties in using formalin-fixed tumor tissue and differences in fixation techniques, problems in the quantitation of the MDR1/P-gp expression levels and heterogeneous staining pattern throughout tumor sections. Moreover, there is no diagnostic consensus on defining MDR1/Pgp positivity in case of preferentially cytoplasmic rather than membrane staining. 4 Additionally, an approach that measures a single feature to predict response is generally not suitable to identify alternative treatment options.
Since different studies demonstrated that gene expression profiles of cancer cell lines 5, 6 as well as primary neoplasms 7, 8 could predict the response to a defined anticancer drug treatment regime, DNA array technology for mRNA expression profiling offers new approaches for solving the diagnostic problem. However, up to date, the majority of studies investigating cancer specimens by DNA microarrays have concentrated on the classification of tumor subtypes and patient prognosis rather than on drug response. [9] [10] [11] Clinical specimens were investigated on drug resistance in esophageal tumor. 12 Another study 13 performed in colon cell lines investigated the correlation of response to 5-fluorouracil and camptothecin and their expression patterns. As these studies focused on a single cancer entity combined with a limited set of treatment, their prediction profile is not applicable for other cancer entities. A different approach has been applied in a study investigating the resistance pattern of human cancer xenografts implanted into nude mice. 14 To obtain predictors for a variety of commonly used drugs for cancer treatment, we have analyzed expression profiles of 30 human cancer cell lines. Since it is generally accepted that most drug resistance mechanisms evolve similarly in tumor cells of different histogenesis, e.g., P-gp overexpression in colon cancer, renal cancer and lung cancer and even in sarcomas, we examined cell lines of different origin. This helps to determine the most significant genetic alterations. Molecular signatures of the cell lines were correlated with the resistance status to 11 anticancer agents at clinically relevant concentrations.
Material and methods

Cell lines and cell culture
In our study, we used 30 human cancer cell lines (see Fig. 2 ). The cells were cultured in Leibovitz L-15 medium (Bio Whittaker, Walkersville, MD, USA) supplemented by 10% fetal calf serum (Gibco BRL, Grand Island NY, USA), 1 mM L-glutamine, 80 IE/l insulin, 2.5 mg/l transferrin, 1 g/l glucose, 1.1 g/l NaHCO 3 , 1% minimal essential vitamins and 20,000 kIE/l trasylol in a humified atmosphere in 5% CO 2 at 37°C. Prior to resistance testing, Mycoplasma tests were performed using the Venor Mp kit, according to the manufacturer's instructions (Minerva Biolabs GmbH, Berlin, Germany).
Resistance tests
Drugs were used in their commercially available form (except cyclophosphamide, which was used in its activated form). Each drug was applied to the cells in 3 concentrations (C1, C2, C3). C1 5 10 21 3 C2 and C3 5 10 3 C2. Concentration C2 was deduced from levels assessed to be clinically achievable in tumor tissue, 15 as discussed previously 16 (Table I) .
In each experiment, 500 cells/microtiter dish were seeded onto 96-well plates. After 2 days, precontrol cells were fixed and stained using sulforhodamine B (SRB). 17 At the same time, triplicate cultures were prepared with all 11 studied drugs at C1, C2 and C3 concentrations. After 4 days, incubation was terminated by replacing the medium with 10% trichloroacetic acid, followed by incubation at 4°C for 1 hr. Subsequently, the plates were washed 5 times with water and stained by adding 100 ll 0.4% SRB (Sigma, St. Louis, MO, USA) in 1% acetic acid for 10 min at room temperature. Washing the plates 5 times with 1% acetic acid eliminated unbound dye. After air-drying and resolubilization of the protein-bound dye in 10 mM Tris-HCl (pH 8.0), absorbance was read at 562 nm in an Elisa-Reader (EL 340 Microplate Bio Kinetics Reader, BIO-TEK Instruments, Winooski, VT, USA). The measurements were performed in triplicates in 3 independent experiments. For the calculation of the RI values, the averages of all 9 measurements were used.
The resistance index (RI) was estimated by the formula RI ¼ ðn post =n pre Þ3½ðn 2 À n pre Þ=ðn post À n pre Þ3100
where n pre is the medium absorbance value of precontrol at the C2 concentration, n post is the medium absorbance value of control and n 2 is the medium absorbance value of stained cells tested with chosen concentration of studied drug (see Fig. 3 ). At the C2 concentration of topotecan and mitoxantrone, we didn't have enough resistant and sensitive cell lines to be able to perform a robust statistical calculation; therefore, we have used the C3 concentration for topotecan and the C1 concentration for mitoxantrone. Only cell lines that fulfilled the following quality criteria of n post > n pre and deviation in cell growth within repetitions <15% were included in the evaluation. Cells exhibiting the lowest third RI results were designated as sensitive, the top third as resistant and the remaining cells were intermediate.
RNA isolation
RNA was isolated from 1 3 10 7 cells in logarithmic growth phase, using the Qiagen Rneasy Mini Kit, following the manufacturer's protocol (Qiagen GmbH, Hilden, Germany). The total isolated RNA was quantified by UV-spectroscopy and its quality was checked by analysis on a LabChip (BioAnalyzer, AGILENT Technologies, Santa Clara, CA). Samples were stored at 280°C until RNA hybridization.
RNA preparation
cDNA was synthesized from 5 lg total RNA, starting with the annealing to 5 pmol/ll T7-(dT)24 primer (HPLC purified, MWG-Biotech, Ebersberg, Germany) at 70°C for 10 min. Reverse transcription, second-strand synthesis and cleanup of double-stranded cDNA were performed according to the Affymetrix protocols. Synthesis of biotin-labeled cRNA was performed using the BioArray High Yield RNA Transcription kit (Enzo Diagnostics, Farmingdale, NY). cRNA concentration was determined by UV-spectroscopy and the distribution of cRNA fragment sizes was checked by analyzing the samples on a LabChip (BioAnalyzer).
Hybridization protocol
The fragmented cRNA was hybridized to the HGU133 array (Affymetrix, Santa Clara, CA) at 45°C in a hybridization oven for 16 hr. Subsequent washing and staining of the arrays were performed using the GeneChip fluidics station protocol EukGE-WS2. Finally, probe arrays were scanned using the GeneChip System confocal scanner (Hewlett-Packard, Santa Clara, CA).
TaqMan quantitative gene expression measurement
To validate the results obtained by the Affymetrix HGU133 chips, we have performed TaqMan verification for expression of 46 selected genes in all 30 cell lines, using an Applied Biosystems 7900HT Micro Fluidic Card System. The measurements were per- Statistical analysis of microarray data Quality control analyses were performed according to the suggestions of The Tumor Analysis Best Practices Working Group. 18 Scanned images with artifacts were excluded, and only arrays showing a percentage of present calls >25% and ratio of the 3 0 -5 0 glyceraldehyde 3-phosphate dehydrogenease (GAPDH 3 0 /5 0 ) <3 were considered. According to the above-mentioned recommendations, we have applied following normalization methods: variance stabilization normalization (VSN), 19 MAS 5.0 [www.affymetrix.com], and RMA. 20 Further data analysis and interpretation has been carried out with all of these pre-processing methods to yield the best comparison and normalization properties across all measurements.
We have arranged the complete dataset consisting of 30 expression profile measurements into 2 classes, according to the resistance properties of the cell lines. Intermediate cell lines were excluded. This selection procedure resulted in 11 datasets, which were treated as autonomous classification tasks. To obtain characteristic gene signatures with high predictive power, we have applied the following feature selection methods: multivariate statistics, shrunken centroids (PAM) 21 and local shrinkage (SAM). 22 Notably, the best and most robust predictive gene list was extracted with the use of PAM by reiterating the procedure on the training-dataset up to 100 times and by selecting the optimal threshold with the smallest cross-validation error.
The dataset was randomly divided into training-and test datasets before the feature selection process was performed (Fig. 1a ). The predictive marker sets were optimized during the reiterative process only on the basis of the training-datasets and were applied to the test set classes thereafter. Since the test datasets are not included in the derivation of the markers, the true error rates can be estimated. 23 The splitting algorithm has been used not only to create a new subset of features (genes) for every training-dataset, but also to investigate the frequency of occurrence of the genes, which were selected in most tests by each single feature selection process. The emerging gene ranking allows the estimation of the heterogeneity and reliability of the class prediction. The statistical significance of every gene-set is tested by randomizing the class assignment in the training dataset and the test data class prediction based on this assignment subsequently. 24 The best feature set, i.e., the amount of features with the most minimal error and sufficient high significance, can be obtained using this method.
The predictive accuracy of the gene sets was tested by k-foldcross-validation-procedures and bootstrapping algorithm with support vector machines (SVM). 25 The specificity and sensitivity of the classification based on given features was computed as described previously. 26 
Results
RI assays
Prior to microarray analysis, we measured drug resistance of 30 cancer cell lines, as described in Material and Methods (Fig. 2) . We have included the representation of drugs for the major anticancer agent classes: alkylating agents (cyclophosphamide, mitomycin C), antimetabolite (5-fluorouracil, methotrexate), antibiotics (doxorubicin, mitoxantrone), topoismorase inhibitors (etoposide, topotecan), vinca alkaloid (vinblastine), taxane (paclitaxel) and the platinum derivative cisplatin. We have summarized the results of the resistance tests in Figure 2 . As a representative example, the RI values of the MDA231 mammary carcinoma cancer cell line at 3 different drug concentrations are depicted in detail ( Fig. 3) .
Identification of discriminatory genes
To identify discriminatory genes, we divided the gene expression profiles obtained for all cell lines into 2 sets associated with the resistance or sensitivity towards each drug as defined by RI. The complete microarray dataset is shown as supplementary infor- Each drug was applied in 3 concentrations (C1, C2, C3), where C1 5 10 21 3 C2 and C3 5 10 3 C2. Concentration C2 is equivalent to drug levels achievable systemically in patients. The RI was estimated by the formula: RI 5 (n post /n pre ) 3 [(n 2 2n pre )/ (n post 2n pre ) 3 100], where n pre is the medium absorbance value of precontrol, n post is the medium absorbance value of control, n 2 is the medium absorbance value of stained cells tested with the chosen concentration. Supplemental Table 1 . Supplementary material for this article can be found on the International Journal of Cancer website at http://www.interscience.wiley.com/jpages/0020-7136/suppmat.). Genes that were associated with the resistance after at least one normalization procedure were included in the list. Resistance to 5fluorouracil was correlated with 237 genes, to cisplatin with 230 genes, to cyclophosphamide with 42 genes, to doxorubicin with 253 genes, to etoposide with 202 genes, to methotrexate with 198 genes, to mitomycin C with 190 genes, to mitoxantrone with 197 genes, to paclitaxel with 139 genes, to topotecan with 297 genes and to vinblastine with 217 genes, respectively. The complete list of genes and its relation to each agent is presented in the Supplemental Table 2 . The list of the common genes associated with the resistance toward at least 4 different agents is presented on Table  II . Important multidrug-resistance-associated functional groups could be the TGF beta pathway (SERPINE1, LTBP2) and various zinc-ion binding proteins (BIRC2, TRIM2 and MMP1). Interestingly, 10 of the top genes were present with several probes (SER-PINE1, NMT2, TFPI2, CTH, FDFT1, FYN, MAC30, PRG1 twice and the ADD3 three times); this also proves the robustness of the performed analysis. One of the top candidate genes is TFPI (tissue factor pathway inhibitor), which is present all together by 5 clones. An example for the correlation between significance and the number of features used for the prediction, including the relative error obtained by random feature selection, is presented in Figure 1b . We have validated the prediction accuracy for the investigated cell lines, using a leave-one-out cross validation, the results are depicted in Figure 4 . We had correct prediction in 220 cases (86% of the classifiable RI tests) and false predictions in 36 cases (14%).
Hierarchical clustering
We have clustered the expression profiles of all cell lines, using the complete dataset to detect similarities across the cell lines. The clustering dendrogram shows that the cell lines derived from ovaries and melanomas were categorized into close branches. However, the cell lines derived from carcinomas of the breast, lung, colon and prostate as well as hepatocellular carcinomas were not clustered into single branches; thus, indicating that those tumors had heterogeneous expression profiles that reflected wider differences in their histological and biological characteristics (Fig. 5a) .
FIGURE 4 -Prediction of drug resistance for the investigated cell lines. 100 represents maximal resistance and 0 maximal sensitivity. Blue boxes represent correct prediction (n 5 220). Grey represents the measurements, where resistance/sensitivity could not be determined during the cell culture experiments (n 5 58). Red and green boxes represent false predictions (red, false sensitive; green, false resistant; n 5 36).
To visualize and confirm discriminatory expression changes, we have also clustered the selected gene lists for the resistant and sensitive samples. As a representative example, the clustering results of genes associated with cisplatin resistance are presented on Figure 5b .
Gene ontology of selected features
We have grouped the selected discriminative genes according to the Kyoto Encyclopedia of Genes and Genomes (KEGG). The analysis was restricted by the availability of annotated genes represented on the U133A GeneChip. The descriptions of the top multidrug resistance candidate genes are included in Table II and  in the Supplemental Table 2 . We have also mapped the selected features to chromosomes, but we have not observed hotspots, which could suggest chromosomal abnormalizations gained by the cancer cells (data not shown).
TaqMan validation
TaqMan real-time RT-PCR was performed to confirm the predictive potential for a selected set of 46 genes. Selection criteria for genes were involvement with the resistance against several drugs and the availability of TaqMan probes. The complete results of the TaqMan measurements are presented in Supplemental  Table 4 . As several of the selected genes were involved in the resistance against more than 1 anticancer agent, altogether 76 pre-dictive gene-agent pairs could be verified at a significance of p < 0.05. In Table III , we have summarized the significant prediction properties for the selected genes for the corresponding agents. The expressions of proteoglycan 1, SOAT1, TFPI and CAT as well as the involvement in correlation in the doxorubicin, 5-fluorouracil, mitomycin C and topotecan resistance patterns are depicted as examples in Figure 6 .
Discussion
We have compared gene expression profiles of pre-characterized drug-sensitive and drug-resistant cancer cell lines of different tumor entities. Accepting that the basic mechanisms of drug resistance are independent of tumor cell histology, this approach contributes to broadly mirror the spectrum of genetic alterations associated with the ineffectiveness of cytostatic drugs. On this basis, we have identified specific gene expression signatures associated with the preexisting resistance at clinically relevant concentrations of 5-fluorouracil, cisplatin, cyclophosphamide, doxorubicin, etoposide, methotrexate, mitomycin C, mitoxantrone, paclitaxel, topotecan and vinblastine.
Further, the use of a set of various cell lines for the construction of our predictor profiles allows a tissue-independent application. A similar approach has been used in a previous study investigating $9,000 genes in 39 cell lines. 27 In another study, gene expression profiling has been used for identifying factors related to the resistance toward selected cytotoxic drugs in 60 cell lines. 5, 28 The major difference and improvement from the oncologist's point of view in our study compared to those investigations is the application of anticancer drugs at concentrations clinically relevant in tumor tissues. In other studies, the actual drug concentration for defining a therapeutic response as opposed to the resistance was chosen to represent the GI 50 value, which is equivalent to drug levels achieving 50% growth inhibition. As in clinical practice, a very low level of drug resistance, i.e. 2-fold, can prevent a successful chemotherapeutic treatment of cancer patients, the GI 50 drug concentration is usually artificial and less relevant. To include the effects of pharmacokinetics (e.g., bioavailability, dilution volume, clearance, mean residence time etc.), we decided to measure the resistance at a pre-defined concentration, which is equivalent to the clinically achievable concentration as discussed previously. 16 Furthermore, additionally to the selection of clinically achievable concentrations, chemotherapeutic antineoplastic agents that are commonly included in clinical therapy protocols as a stand-alone agent or in at least one combination protocol were chosen (Table I) .
To overcome the risk of overfitting the prediction model to a limited data set, we splitted the available expression profiles of cell lines into a test set and a training set. We rotated the data sets and recalculated the list of significant genes for each compound 100 times, and selected genes with high repeated (reproducible) prevalence. The gene list in a leave-one-out cross validation allowed to predict resistance in more than 80% of the tests correctly.
We have found a total of 1,481 genes associated with drug resistance. Out of these genes, 1,033 genes were associated with merely a single anticancer agent, 271 genes with 2 and 110 with 3 anticancer agents. This small overlap among the established gene lists supports the current concept that anticancer drug resistance is a highly complex phenomenon resulting of various interacting molecular mechanisms that can be switched on and off and temporarily being simultaneously active. We also identified 67 multidrug resistance candidate genes associated with resistance toward 4 or more anticancer agents, suggesting that these are correlated with common mechanisms involved in drug response (Fig. 4) . Particularly interesting candidate genes were probes present in at least 6 resistance patterns. The list includes the genes encoding tripartite motif-containing 2 (TRIM2), apoli-poprotein B mRNA editing enzyme (APOBEC3B), baculoviral IAP repeat-containing 2 (BIRC2), tissue factor pathway inhibitor 2 (TFPI2) and chromosome 10 open reading frame 38 (C10orf38). Of these, only BIRC2 has already been associated with tumor resistance: it is upregulated in radioresistant oesophageal cancer cell lines. 29 TFPI is not only the major physiologic inhibitor of the extrinsic coagulation pathway, but its apoptotic, anitangiogenic and antitumor activity has been also described, 30 TFPI2 is a suggested new target for the treatment of osteoarthritis. 31 APOBEC3B is a potent inhibitor of simian immunodeficiency virus replication. 32 However, for a potential prediction of a drug-resistant phenotype in tumor cells by mRNA expression profiling, it is not important whether the alterations in the expression levels of the identified genes are an effect of functional involvement in drug resistance or merely the result of coregulations or other cellular events.
The Affymetrix HGU133 chips contain the well-known resistance associated MDR1 (209993_at, 209994_at) and MRP1 (202804_at, 202805_at) genes. Interestingly, the average MDR1 expression levels were more than 4-fold increased when compared to the MRP1 expression levels (normalized; log 2 scale: MDR1, 6.36 6 0.71; MRP1, 8.47 6 0.46). We have measured the highest MDR1 expression in the hepatocellular carcinoma SNU449 cell line, which was found to be resistant against each tested drug. We have measured high MDR1 expression in CX-2, OAW42, Hep3B, A375 and Colo699-these cell lines are resistant against cyclophosphamide and methothrexate. High MRP1 expression was detected in SNU475, OVCAR3, SKOV-3 and SKBR cell lines, but its overexpression was not linked to the resistance against any cytotoxic drug. These data supports the role of the ABC transporters in drug resistance, but also emphasize the role of additional mechanisms involved in drug resistance.
Since no gene was associated with drug resistance against all of the investigated drugs, the study suggests that a set of universal resistance genes cannot be identified. This finding is in line with results in a previous study investigating gene patterns associated with resistance against 4 anticancer drugs in acute lymphoblastic leukemia. 8 Previously, attempts using single genes for assessing drug sensitivity have seldomly produced conclusive results. 33, 34 Our results support the concept that different mechanisms are associated with resistance against different drugs, 35 and therefore support the use of combination chemotherapy for cancer treatment. In a similar study, recently performed on the same microarray platform, Kang et al 36 identified gene expression patterns related to resistance against 5-fluorouracil, cisplatin and doxorubicin resistance, respectively, in 14 human gastric cancer cells. We have compared the published set of 250 differentially regulated genes with our prediction profiles. We found only 1 common gene associated with 5-fluorouracil (212614_at), and 2 common genes associated with cisplatin resistance (C6orf37 and DJ971N18.2). We have found a much higher overlap of up-regulated genes in the doxorubicin resistance associated genes (ANKT, BUB1B, CENPA, HCAP-G, HMGB2, HMMR, KIAA0101, KIF4A, LMNB1, MAD2L1, MGC5528, OIP5, PRC1, TOP2A and ZWINT). These results are in line with the findings of a recent study demonstrating that different gene signatures can achieve similar prediction success for the same classification problem. 37 Interestingly, only 2 of the top 67 multidrug-resistance associated genes were previously identified to be associated with resistance in drug resistant cell lines in vitro. Elevated expression of the Matrix Metalloproteinase 1 (MMP1) was found in breast carcinoma cells with intrinsic and acquired doxorubicin resistance. 38 In 5 breast cancer cell lines, the coexpression of EGFR or ErbB3 with ErbB2 was found to induce high phosphorylation of ErbB2 and render the cells more resistant to various anticancer drugs, including 5-fluorouracil and doxorubicin. 39 Additional evaluation of the selected genes in multidrug resistant cell lines will be needed to verify the casual involvement of these genes in drug resistance.
A key concern with the use of cDNA microarray analysis in relation to cancer therapy is that the evaluation of a larger number of genes may identify such a sizeable number of potential target genes that it would be unfeasible to try to confirm the involvement of each of these genes in the resistance. To reduce the experimental variation, we have performed 3 different normalization methods (VSN, MAS and RMA). Thus, the main remaining issue is the variation of the Affymetrix results for 1 sample-in other words the reproducibility of the measurement. In this study, 46 of the drug-resistance related genes were also measured by TaqMan real time RT-PCR. We have decided to measure a relative high number of features compared to earlier studies to achieve robust validation for the microarray data. During the selection, we have focused on genes that were preferentially present in more than 1 resistance pattern. However, because of the lack of established TaqMan probes, we were not able to select all of the relevant genes with highest predictive power. The differential expression on the TaqMan correlated strongly with the results obtained by the Affymetrix arrays even in correlation with different drugs for most analyzed genes (e.g. TFPI2 and mitomycin C resistance, p < 0.01; NMT2 and topotecan resistance, p < 0.05; ADD3 and doxorubicin resistance, p < 0.05). However, the correlation for some genes was not significant (e.g. SERPINB2 and vinblastine resistance, RAGE and paclitaxel resistance, PHLDA1 and cisplatin resistance). Overall, the differences in RNA expression and their involvements in the predictive gene sets were confirmed by the TaqMan array analysis for most of the selected genes (Table III) .
In summary, we have identified predictive sets of marker genes for simultaneous assessment of the sensitivity to eleven selected chemotherapeutical agents at clinically relevant concentrations. Our results suggest that DNA microarray technology can help to classify cancer cell lines for drug resistance and sensitivity effectively. Since the study focused on the resistance at clinically relevant anticancer drug concentrations, cancer response prediction may be applicable in the future. The expression patterns validated by quantitative RT-TCR provide new gene candidates associated with multidrug resistance. To verify the predictors identified in well-established in vitro models, they have to be scrutinized with heterogeneous clinical specimens from large cohorts of cancer patients. However, for identification of potential new factors functionally involved in drug resistance, the expression analyses are not directly useful. For identification of such factors, additional hypothesis-driven studies are necessary.
